preterm birth
Mirvie Raises $60M in Series B Funding
The company plans to use the funding to propel the clinical and commercial development of its Mirvie RNA testing platform for pregnancy health.
The South San Francisco-based startup recently published two studies showing the performance of its tests for predicting preterm birth and preeclampsia.
Oppenheimer Initiates Coverage of Sera Prognostics at Outperform
The investment bank said Sera's primary product has the potential to create a new market for blood-based testing to assess preterm birth risk.
The report recommended against the use of markers including fetal fibronectin and Sera Prognostics' PreTRM test due to low positive predictive value.
New AACC Guidance Advises Against Using Tests to Predict Premature Birth
The guidance cites evidence that premature birth tests don't improve outcomes for patients at risk of premature delivery or their babies.